Alimentiv, Dova Launch AI UC Scoring Solution at DDW 2025 in San Diego

Alimentiv and Dova Health Intelligence (formerly Satisfai Health Inc.) announced the launch of DovaVision™, an artificial intelligence solution for ulcerative colitis (UC) scoring, during the Digestive Disease Week (DDW) conference in San Diego in 2025. This innovation represents a significant step forward in clinical trial technology for UC, enhancing both the accuracy and efficiency of disease assessment. Key Features of DovaVision™ DovaVision™ is designed specifically for interpreting endoscopy images in UC clinical trials. It leverages advanced dynamic frame-level analysis to detect and quantify subtle changes in lesions, providing researchers and sponsors with more detailed and quantifiable assessments of disease severity. The AI tool supports all phases of UC clinical trials, from Phase I to Phase IV, improving the quality and depth of image data. This capability results in better-informed decisions about treatment efficacy, patient condition, and overall trial progression. Development and Integration The development of DovaVision™ involved a comprehensive database of anonymized inflammatory bowel disease (IBD) colonoscopy videos sourced globally. Alimentiv’s team of expert central readers and medical professionals provided critical clinical insights and data annotations, ensuring that the AI model is trained on high-quality, relevant data. Solveig Johannessen, CEO of Dova Health Intelligence, emphasized that the tool is designed to meet the demands of precision medicine by offering deeper data-driven insights beyond traditional centralized scoring methods. Michael Byrne, a gastroenterologist and founder and chairman of Dova Health Intelligence, highlighted the tool’s potential to revolutionize UC clinical trials. He noted that automatic, consistent frame-level analysis will outperform manual scoring, allowing for seamless integration with other clinical datasets. This can lead to valuable biomarker correlations and a better understanding of the disease's mechanisms and treatment responses. Pierre Gaudreault, CEO of Alimentiv, expressed enthusiasm about incorporating DovaVision™ into their existing medical imaging portfolio. He stated that the technology will enable more detailed reporting, lower clinical trial costs, and shorter trial durations, maintaining Alimentiv’s leadership in the industry. Current Usage and Scope At present, DovaVision™ is restricted to research purposes and is delivered through Alimentiv’s proprietary multimodal imaging review platform, Notō™. Notō™ offers an end-to-end solution for image data analysis and scoring. While DovaVision™ excels in data analysis, it is not classified as a medical device and is not intended for clinical decision-making, diagnosis, or patient care by healthcare professionals. Benefits and Impact The introduction of DovaVision™ is expected to facilitate faster and more accurate research in UC. By providing detailed, data-supported insights, it can aid in the optimization of trial design and interpretation of results. The tool’s original data output can be combined with other clinical datasets, enabling researchers and sponsors to explore the relationships between endoscopic imaging biomarkers and patient outcomes. This integration promises to enhance the evidence base for studies on disease mechanisms and therapeutic responses. Industry Insights and Company Profiles Industry insiders view DovaVision™ as a major breakthrough in gastrointestinal disease research. It is seen as a crucial milestone in improving the quality and efficiency of UC clinical trials, paving the way for more rapid development of new treatments and ultimately benefiting patients. Alimentiv, established in 1986, is a leading global full-service contract research organization (CRO) specializing in gastrointestinal diseases. The company has extensive experience in clinical trials, medical imaging, and precision medicine, offering a wide range of services and solutions to the pharmaceutical and biotech industries. Dova Health Intelligence, headquartered in Vancouver, Canada, focuses on advancing gastrointestinal care and research through artificial intelligence. The company develops various intelligent products to provide valuable insights and support decision-making for researchers, doctors, and pharmaceutical innovators. The collaboration between Alimentiv and Dova Health Intelligence underscores a commitment to leveraging cutting-edge technology in the pursuit of more effective therapies. Together, they aim to accelerate the development of novel drugs, improve patient treatment outcomes, and advance the field of precision medicine. In summary, the launch of DovaVision™ at DDW 2025 marks a significant advancement in UC clinical trials, driven by the synergy of Alimentiv’s expertise in gastrointestinal research and Dova Health Intelligence’s innovative AI capabilities. This tool is poised to transform the way UC is assessed and studied, potentially leading to quicker and more reliable drug development processes, which could benefit countless patients in the near future.